Normalization of glucose homeostasis by a long-acting somatostatin analog SMS 201-995 in a newborn with nesidioblastosis.
A female child was admitted to the hospital few days after birth with severe hypoglycemia and convulsive episodes. Plasma insulin levels were elevated and oral and intravenous administration of glucose were unable to keep blood glucose above 2 mmol/l limit. Intravenous infusion of a long acting somatostatin analog, SMS 201-995, at a dosage gradually increasing from 2 to 50 micrograms/24 hr, was accompanied by a dramatic fall in circulating insulin levels. Normality of glucose homeostasis was restored and convulsive spells ceased. Fasting blood glucose levels stabilized between 3.4 and 4.7 mmol/l. No rebound phenomenon was observed during short term interruptions of the SMS 201-995 infusion. A subtotal pancreatectomy was performed during SMS treatment, and the diagnosis of nesidioblastosis was confirmed by immunocytologic and electron-microscopic studies. It is concluded that this new potent and long acting somatostatin derivative may be useful in the management of hyperinsulinism in the neonate.
D001786:Blood Glucose / Q000378:metabolism; D005260:Female; D006706:Homeostasis; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy* / Q000209:etiology; D007231:Infant, Newborn; D007328:Insulin / Q000097:blood; D015282:Octreotide; D010180:Pancreatectomy; D010182:Pancreatic Diseases / Q000150:complications* / Q000628:therapy; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D001786:Blood Glucose; D007328:Insulin; D013004:Somatostatin; D015282:Octreotide